T. Rowe Price Associates’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-80,336
| Closed | -$149K | – | 3021 |
|
|
2023
Q1 | $149K | Hold |
80,336
| – | – | ﹤0.01% | 2597 |
|
|
2022
Q4 | $89K | Buy |
80,336
+41,000
| +104% | +$45.4K | ﹤0.01% | 2738 |
|
|
2022
Q3 | $93K | Buy |
39,336
+19,718
| +101% | +$46.6K | ﹤0.01% | 2741 |
|
|
2022
Q2 | $59K | Sell |
19,618
-44,691
| -69% | -$134K | ﹤0.01% | 2834 |
|
|
2022
Q1 | $437K | Buy |
64,309
+54,115
| +531% | +$368K | ﹤0.01% | 2389 |
|
|
2021
Q4 | $85K | Sell |
10,194
-191,300
| -95% | -$1.6M | ﹤0.01% | 2888 |
|
|
2021
Q3 | $1.5M | Buy |
201,494
+15,636
| +8% | +$116K | ﹤0.01% | 1849 |
|
|
2021
Q2 | $1.26M | Buy |
185,858
+45,232
| +32% | +$308K | ﹤0.01% | 1957 |
|
|
2021
Q1 | $1.44M | Buy |
140,626
+35,630
| +34% | +$366K | ﹤0.01% | 1860 |
|
|
2020
Q4 | $735K | Buy |
+104,996
| New | +$735K | ﹤0.01% | 2078 |
|